UNICREDIT BANK/CALL/BIOGEN IDEC/350/0.1/15.01.25 | Real-time BOERSE MUENCHEN 01:11:46 10/06/2024 pm IST | ||
| 0.28 EUR | 0.00% |
|
| Current month | -6.67% | ||
| 1 month | +86.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 0.28 | 0.00% |
| 07/24/07 | 0.28 | -22.22% |
| 06/24/06 | 0.36 | -2.70% |
| 05/24/05 | 0.37 | +5.71% |
| 04/24/04 | 0.35 | -2.78% |
Real-time BOERSE MUENCHEN
Last update June 10, 2024 at 01:11 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC3LKP |
| ISIN | DE000HC3LKP6 |
| Date issued | 27/01/2023 |
| Strike | 350 $ |
| Maturity | 15/01/2025 (220 Days) |
| Parity | 10 : 1 |
| Emission price | 5.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.87 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.32 € |
| Spread % | 80.00% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
225.4
USD
Average target price
284.6
USD
Spread / Average Target
+26.26%
- Stock Market
- Warrants
- Warrant
